Evaluation of anti-emetic efficacy of Aprepitant in patients undergo hematopoitic stem cell transplantation in a teaching hospital

Phase 2

• Conditions: Other transplanted organ and tissue status; Condition 1: Autologous bone marrow transplantation. Condition 2: emesis.; Haematemesis

• Registration Number: IRCT201107026930N1
• Lead Sponsor: Vice chancellor for research, Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

patients who undergo autologus bone marrow transplantation. Exclusion criteria: severe hepatic and renal failure during drug administration; hypersensitivity to the drug.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The patient's nutritional status. Timepoint: 5 days prior to the intervention until after patient discharge. Method of measurement: Ask the patient.;The need for tpn. Timepoint: 5 days prior to the intervention until after patient discharge. Method of measurement: Recorded in the file.;Number of vomiting. Timepoint: 5 days prior to the intervention until after patient discharge. Method of measurement: Ask the patient - the nurse reported.;Nausea. Timepoint: 5 days prior to the intervention until after patient discharge. Method of measurement: Ask the patient.